4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $40.00 to $39.00. They now have an "outperform" rating on the stock.
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV